Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q4 2020 · 10-K
Revenue$11.42M$11.42M−7.0% vs Q4 2019 Net Income-$62.50M-$62.50MN/M vs Q4 2019 EPS Diluted-$1.00-$1.00no prior Q4 2019 on file Operating Incomederived-$65,874,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
Operating Cash Flowderived-$40,100,000N/M Free Cash Flowderived-$41,476,000N/M Margins · derivedOperating margin-576.9%−256.0 pt vs Q4 2019
Net margin-547.3%−239.9 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 26, 2021 · 57 d after period end